Abstract
Twenty-four patients with advanced lymphoma were treated with uracil-chlorethamine. The starting dose was 2 to 3 mg by mouth daily until maximum therapeutic effect or severe hematologic toxicity developed. This period of time ranged from 20 to 185 days (median 30) for a total dose ranging from 0.7 to 5.1 mg/kg (median 1.3). Maintenance treatment was given to 13 patients at the dose of 1 mg per day for 5 to 7 days per week. In the induction phase, therapeutic effects were obtained in 13 out of 24 (54 %), all pretreated patients. However, complete or incomplete remissions were observed in only 5 out of 24 (21 %) cases. Severe, although reversible, hematologic toxicity (i. e. blood leukocytes < 1000 and/or platelets < 50.000/mmc) was observed in 5 out of 24 cases. It was not strictly dose-related and it was often unpredictable. Altogether, as remission inducer, uracil-chlorethamine appeared to be moderately active and not easy to handle. On the other hand the drug proved able to maintain or improve a remission (induced by the same or other agents) for periods of time up to 24 months (median 6), with minimal or no toxicity.
Get full access to this article
View all access options for this article.